Phenosense

Monogram Announces 2008 Second Quarter Financial Results

... revenue from Trofile(TM) for selecting HIV patients to be treated with Selzentry(TM), Pfizer's CCR5 antagonist, and by revenue from use of Monogram's phenosense HIV(TM) resistance test and Trofile in a phase III trial by a pharmaceutical company customer. Revenue for the six months ended June 30, 2008 was $3...

Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies

... phenosense GT(TM) and phenosense Integrase(TM) assays used to study ...type and genotype drug results in a single report. phenosense GT also includes a measure of replication capacity...

Phenosense in Medical Technology

Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor

...trains of HIV. Additionally, the unique structural properties of SPI-256 explain its high potency when tested against a panel of 50 viral strains in a phenosense (TM) assay. In this analysis, SPI-256 achieved potency levels 4- to 50-fold higher than currently approved front-line protease inhibitors when tested ...

Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials

...ooking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements. Trofile and phenosense GT are trademarks of Monogram Biosciences, Inc. contacts: Alfred G. Merriweather Jeremiah Hall Chief Financial Officer F...

DHHS Guidelines Support Use of Trofile(TM) Assay Prior to CCR5 Inhibitor Use

...ooking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements. Trofile and phenosense GT are trademarks of Monogram Biosciences, Inc. Contacts: Alfred G. Merriweather Jeremiah Hall Chief Financial Officer ...

Phenosense in Medical Products

HIV Phenosense GT

Description: ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' client...
Company:ARUP Laboratories

Phenosense in Biological Technology

Monogram Announces 2008 Third Quarter Financial Results

... revenue from Trofile(TM) for selecting HIV patients to be treated with Selzentry(TM), Pfizer's CCR5 antagonist, and by revenue from use of Monogram's phenosense HIV(TM) resistance test and Trofile in a phase III trial by a pharmaceutical company customer. Revenue for the nine months ended September 30, 2008 ...

Medical Policy Guideline for Trofile(TM) Established By Wellpoint, Inc.

...ces to the use of our resistance assays, including phenosense Integrase, and our Trofile Assay, the size and tim...circumstances after the date of such statements. phenosense and phenosense GT are registered trademarks and Trofile is a trad...

Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors

...nto the DNA of newly infected cells. Together with phenosense GT(R), PhenoSense Integrase provides the most comp...cture of resistance to antiretroviral therapies. phenosense Integrase along with other Monogram assays were us...Phase III studies. In addition to drug resistance, phenosense Integrase also measures reductions in viral replic...

Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts

...ny forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements. phenosense GT is a trademark of Monogram Biosciences, Inc. Contacts: Alfred G. Merriweather Jeremiah Hall Chief Financial Officer Feinstein...

Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity

...m's tests have been used throughout the development of the CCR5 class of drugs. In addition to the use of Trofile for patient selection and the use of phenosense for optimization of background therapy in the phase II and phase III clinical trials of Pfizer's maraviroc (Selzentry(TM)) and Schering Plough's vicri...